Dongwha Pharm.Co.,Ltd

KOSE:A000020 Stock Report

Market Cap: ₩168.8b

Dongwha Pharm.Co.Ltd Past Earnings Performance

Past criteria checks 1/6

Dongwha Pharm.Co.Ltd has been growing earnings at an average annual rate of 4.5%, while the Pharmaceuticals industry saw earnings growing at 7.3% annually. Revenues have been growing at an average rate of 7.6% per year. Dongwha Pharm.Co.Ltd's return on equity is 1.4%, and it has net margins of 1.8%.

Key information

4.5%

Earnings growth rate

4.4%

EPS growth rate

Pharmaceuticals Industry Growth11.3%
Revenue growth rate7.6%
Return on equity1.4%
Net Margin1.8%
Last Earnings Update30 Sep 2024

Recent past performance updates

Dongwha Pharm.Co.Ltd's (KRX:000020) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Nov 20
Dongwha Pharm.Co.Ltd's (KRX:000020) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Dongwha Pharm.Co.Ltd's (KRX:000020) Promising Earnings May Rest On Soft Foundations

Mar 26
Dongwha Pharm.Co.Ltd's (KRX:000020) Promising Earnings May Rest On Soft Foundations

Recent updates

Dongwha Pharm.Co.Ltd's (KRX:000020) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Nov 20
Dongwha Pharm.Co.Ltd's (KRX:000020) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Dongwha Pharm.Co.Ltd's (KRX:000020) Promising Earnings May Rest On Soft Foundations

Mar 26
Dongwha Pharm.Co.Ltd's (KRX:000020) Promising Earnings May Rest On Soft Foundations

Is Dongwha Pharm.Co.,Ltd (KRX:000020) A Smart Pick For Income Investors?

Apr 28
Is Dongwha Pharm.Co.,Ltd (KRX:000020) A Smart Pick For Income Investors?

These 4 Measures Indicate That Dongwha Pharm.Co.Ltd (KRX:000020) Is Using Debt Safely

Mar 11
These 4 Measures Indicate That Dongwha Pharm.Co.Ltd (KRX:000020) Is Using Debt Safely

Dongwha Pharm.Co.,Ltd (KRX:000020) Has A ROE Of 8.6%

Feb 22
Dongwha Pharm.Co.,Ltd (KRX:000020) Has A ROE Of 8.6%

Is Dongwha Pharm.Co.Ltd's (KRX:000020) Share Price Gain Of 102% Well Earned?

Feb 07
Is Dongwha Pharm.Co.Ltd's (KRX:000020) Share Price Gain Of 102% Well Earned?

Should Dongwha Pharm.Co.,Ltd (KRX:000020) Be Part Of Your Dividend Portfolio?

Jan 23
Should Dongwha Pharm.Co.,Ltd (KRX:000020) Be Part Of Your Dividend Portfolio?

Is Dongwha Pharm.Co.,Ltd (KRX:000020) Popular Amongst Insiders?

Jan 08
Is Dongwha Pharm.Co.,Ltd (KRX:000020) Popular Amongst Insiders?

Dongwha Pharm.Co.,Ltd (KRX:000020) Pays A ₩120 Dividend In Just Four Days

Dec 24
Dongwha Pharm.Co.,Ltd (KRX:000020) Pays A ₩120 Dividend In Just Four Days

We're Not Counting On Dongwha Pharm.Co.Ltd (KRX:000020) To Sustain Its Statutory Profitability

Dec 19
We're Not Counting On Dongwha Pharm.Co.Ltd (KRX:000020) To Sustain Its Statutory Profitability

Is Dongwha Pharm.Co.Ltd (KRX:000020) Using Too Much Debt?

Dec 04
Is Dongwha Pharm.Co.Ltd (KRX:000020) Using Too Much Debt?

Can Dongwha Pharm.Co.,Ltd (KRX:000020) Improve Its Returns?

Nov 19
Can Dongwha Pharm.Co.,Ltd (KRX:000020) Improve Its Returns?

Revenue & Expenses Breakdown

How Dongwha Pharm.Co.Ltd makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

KOSE:A000020 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24428,4827,673164,44621,583
30 Jun 24405,74613,902159,74820,617
31 Mar 24380,57417,888151,39221,131
31 Dec 23361,10927,438143,56521,548
30 Sep 23361,32629,155138,92020,313
30 Jun 23357,32429,177132,52620,772
31 Mar 23354,55227,685129,16520,524
31 Dec 22340,42620,383125,77419,285
30 Sep 22332,28522,907126,4868,965
30 Jun 22317,90117,410118,87611,463
31 Mar 22306,48517,660108,25117,336
31 Dec 21293,01817,870103,21517,338
30 Sep 21285,37119,92898,99817,459
30 Jun 21282,86831,23895,83217,377
31 Mar 21276,89931,69393,36417,383
31 Dec 20272,07528,50892,55816,912
30 Sep 20286,74628,40589,90117,156
30 Jun 20294,39516,88490,64916,987
31 Mar 20299,4909,53391,42416,581
31 Dec 19307,1509,11690,63616,332
30 Sep 19299,1954,88191,61316,408
30 Jun 19299,8935,82390,68316,183
31 Mar 19304,3027,20289,28515,781
31 Dec 18306,60310,06985,51915,605
31 Dec 17258,88247,00979,45014,078

Quality Earnings: A000020 has a high level of non-cash earnings.

Growing Profit Margin: A000020's current net profit margins (1.8%) are lower than last year (8.1%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: A000020's earnings have grown by 4.5% per year over the past 5 years.

Accelerating Growth: A000020's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: A000020 had negative earnings growth (-73.7%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (25.3%).


Return on Equity

High ROE: A000020's Return on Equity (1.4%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/01 22:05
End of Day Share Price 2025/01/31 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Dongwha Pharm.Co.,Ltd is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Dodo ChengHSBC